| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9567363 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(4 years from now) | |
| US8268800 | OTSUKA | Certain compounds, compositions and methods |
Aug, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618075 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(4 years from now) | |
Inqovi is owned by Otsuka.
Inqovi contains Cedazuridine; Decitabine.
Inqovi has a total of 3 drug patents out of which 0 drug patents have expired.
Inqovi was authorised for market use on 07 July, 2020.
Inqovi is available in tablet;oral dosage forms.
Inqovi can be used as method for inhibiting degradation of a cda substrate by administering cedazuridine.
Drug patent challenges can be filed against Inqovi from 07 July, 2024.
The generics of Inqovi are possible to be released after 22 August, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2025 |
| Orphan Drug Exclusivity(ODE-316) | Jul 07, 2027 |
Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient
NCE-1 date: 07 July, 2024
Market Authorisation Date: 07 July, 2020
Treatment: Method for inhibiting degradation of a cda substrate by administering cedazuridine
Dosage: TABLET;ORAL
INQOVI family patents
